|
|
Vaccine Detail
|
ALVAC-ESO-1 Vaccine |
| Vaccine Information |
- Vaccine Name: ALVAC-ESO-1 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007245
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: NY-ESO-1
- NY-ESO-1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The treatment combines the vaccination of a bacterial vector for NY-ESO-1 and the use of mTOR inhibitor Sirolimus (Thomas et al., 2018).
- Description: A cancer vaccine consisting of a replication-defective recombinant canarypox virus (ALVAC) encoding the cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, ALVAC-ESO-1 vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against NY-ESO-1-expressing cancer cells, which may result in the inhibition of tumor cell proliferation. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cells. (NCIT_C90558).
This vaccine has been used in trials involving epithelial ovarian, fallopian tube, or primary peritoneal cancer. NCT01982487
|
| Host Response |
|
|
| References |
NCIT_C90558: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C90558]
Thomas et al., 2018: Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in immunology. 2018; 9; 947. [PubMed: 29770138].
|
|
